Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders.

Rationale: Medications are urgently needed to treat symptoms of drug withdrawal and mitigate dysphoria and psychiatric comorbidities that drive opioid abuse and relapse. ITI-333 is a novel molecule in development for treatment of substance use disorders, psychiatric comorbidities, and pain.
Objective: Characterize the preclinical profile of ITI-333 using pharmacological, behavioral, and physiological assays.
Methods: Cell-based assays were used to measure receptor binding and intrinsic efficacy of ITI-333; animal models were employed to assess effects on opioid reinstatement, precipitated oxycodone withdrawal, and drug abuse liability.
Results: In vitro, ITI-333 is a potent 5-HT _2A receptor antagonist (K _i  = 8 nM) and a biased, partial agonist at μ-opioid (MOP) receptors (K _i  = 11 nM; lacking β-arrestin agonism) with lesser antagonist activity at adrenergic α _1A (K _i  = 28 nM) and dopamine D ₁ (K _i  = 50 nM) receptors. In vivo, ITI-333 blocks 5-HT _2A receptor-mediated head twitch and MOP receptor-mediated effects on motor hyperactivity in mice. ITI-333 alone is a naloxone-sensitive analgesic (mice) which suppresses somatic signs of naloxone-precipitated oxycodone withdrawal (mice) and heroin cue-induced reinstatement responding without apparent tolerance or physical dependence after chronic dosing (rats). ITI-333 did not acutely impair gastrointestinal or pulmonary function (rats) and was not intravenously self-administered by heroin-maintained rats or rhesus monkeys.
Conclusions: ITI-333 acts as a potent 5-HT _2A receptor antagonist, as well a biased MOP receptor partial agonist with low intrinsic efficacy. ITI-333 mitigates opioid withdrawal/reinstatement, supporting its potential utility as a treatment for OUD.
(© 2024. The Author(s).)